Butter and Salt Builds Job Portal for Ukrainian Refugees

Butter and Salt

Many industrial companies are looking for programmers, designers, developers and other technically trained employees. On the other hand, many well-trained refugees from Ukraine come to Germany and are allowed to enter the job market here directly. Through the new job portal tech-jobs-4-ukrainians.de, it should be made as easy as possible for Ukrainian refugees to be approached by German companies and thus achieve a win-win situation for both sides.

“In our portal, Ukrainians who are looking for a job in technical fields can create a profile. Companies looking for skilled workers can view these profiles. If there is interest in making contact or getting to know each other regarding a possible cooperation, the companies can contact the profile holders,” Florian Schildein, Managing Director of Butter and Salt GmbH, explains the principle of tech-jobs-4-ukrainians.de. Many customers of Butter and Salt GmbH are permanently looking for new skilled personnel. “In some cases, companies have been looking for programmers and similar employees for years. Familiar application processes no longer work here, because there are simply no more free skilled workers on the job market. For many managers, it no longer matters whether an employee speaks German or English. Therefore, we have to turn the search process around. That means companies have to actively approach possible candidates,” Schildein looks back on his own personnel search.

tech-jobs-4-ukrainians.de is a free service for all participants that the team of Butter and Salt has built up over the last few weeks. The costs for this, as well as for the marketing, are and were completely covered by the B2B marketing specialist from Berlin. For Schildein, this is a matter of course: “As an entrepreneur, I am responsible for my company, my employees, my customers and suppliers or partners. But I also have a social responsibility. And if I can do something good with what I do every day, then it is my duty as an entrepreneur to do so within the scope of my possibilities.” The job portal went online after Easter and will now gradually fill up with candidates. The first companies are already using the platform to find suitable candidates.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version